Trial Profile
Multicenter Open Label Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase (Actilyse) in Patients With Acute Ischemic Stroke
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Recombinant staphylokinase Supergene (Primary) ; Alteplase
- Indications Stroke
- Focus Therapeutic Use
- Acronyms FRIDA
- Sponsors Supergene
- 01 Sep 2021 Primary endpoint has been met. (Good functional recovery), as per Results published in the Lancet Neurology
- 01 Sep 2021 Results published in the Lancet Neurology
- 24 Nov 2020 Status changed from recruiting to completed.